A mixture of enantiomers of trans-3-[(4-methoxyphen- oxy)-methyl]-1-methyl-4-phenylpiperidine is separated into the optically active pure forms by reacting it with an enantiomer of mandelic acid or a derivative thereof to form two diastereomeric compounds and by precipitating one of the diastereomeric compounds formed. The precipitated compound is subsequently separated and is optionally converted into the free base or a pharmaceutically acceptable salt thereof. The yield obtained is substantially higher than the yield obtained by a prior art process employing a tartaric acid derivative as resolving agent.
反式-3-[(4-
甲氧基苯氧基)-甲基]-1-甲基-
4-苯基哌啶的对映体混合物通过与
扁桃酸或其衍
生物的对映体反应形成两种非对映化合物,并沉淀所形成的非对映化合物之一,从而分离成光学活性纯形式。 随后分离沉淀的化合物,并将其转化为游离碱或药学上可接受的盐。 所获得的产率大大高于采用
酒石酸衍
生物作为溶解剂的现有技术工艺所获得的产率。